Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Citius Pharmaceuticals, Inc. Director's Dealing 2017

Aug 28, 2017

34965_dirs_2017-08-28_b9dfa976-7af1-4a2f-b310-5b71ad7fe5b6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2017-08-24-06:00

Reporting Person: Mazur Leonard L (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-08-24-06:00 Common Stock P 11000 $2.68 Acquired 3337730 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-08-24-06:00 Warrant to Purchase Common Stock $4.125 P 11000 Acquired 2022-08-08-06:00 Common Stock (11000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Warrant to Purchase Common Stock $6.15 2019-06-12-06:00 Common Stock (19614) 19614 Direct
Warrant to Purchase Common Stock $9.90 2019-09-30-06:00 Common Stock (3171) 3171 Direct
Warrant to Purchase Common Stock $9.90 2020-01-08-07:00 Common Stock (4984) 4984 Direct
Warrant to Purchase Common Stock $7.50 2020-08-18-06:00 Common Stock (35211) 35211 Direct
Warrant to Purchase Common Stock $7.50 2020-11-02-07:00 Common Stock (20783) 20783 Direct
Warrant to Purchase Common Stock $7.50 2020-11-20-07:00 Common Stock (20664) 20664 Direct
Warrant to Purchase Common Stock $7.50 2021-01-08-07:00 Common Stock (13679) 13679 Direct
Warrant to Purchase Common Stock $7.50 2021-03-14-07:00 Common Stock (4210) 4210 Direct
Warrant to Purchase Common Stock $6.15 2021-03-15-06:00 Common Stock (18106) 18106 Direct
Warrant to Purchase Common Stock $4.125 2022-08-08-06:00 Common Stock (421400) 421400 Direct
Options to Purchase Common Stock $6.75 2024-09-12-06:00 Common Stock (220000) 220000 Direct

Footnotes

F1: On August 24, 2017, the Report Person purchased a five-year warrant to purchase 11,000 shares of the Company's common stock at an exercise price of $4.125 per share. The warrant is fully vested and exercisable six months from August 8, 2017.

F2: The warrant is fully vested and exercisable immediately.

F3: On August 8, 2017, the Reporting Person purchased a five-year warrant to purchase 421,400 shares of the Company's common stock at an exercise price of $4.125 per share. The warrant is fully vested and exercisable six months from August 8, 2017.

F4: The option vests as to 40% of the shares of the Company's common stock on September 12, 2014 and 15% of the shares on each of September 12, 2015, March 12 and September 12, 2016 and September 12, 2017. The option was issued pursuant to the Company's 2014 Stock Incentive Plan.